Develops precision medicine therapies for neurodegenerative diseases, focusing on Alzheimer's disease.
ProMIS Neurosciences, Inc. is dedicated to pioneering precision medicine solutions aimed at combating neurodegenerative diseases, with a primary focus on Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). Based in Canada, the company utilizes its proprietary ProMIS and Collective Coordinates algorithms to identify disease-specific epitopes on the surface of misfolded proteins. These novel targets play a crucial role in the development of therapeutic antibodies designed to selectively neutralize toxic oligomers and fibrils implicated in these debilitating conditions.
At the forefront of its product pipeline are several promising candidates. PMN310, a monoclonal antibody, targets toxic oligomers associated with AD, while PMN267 addresses superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha-synuclein in Parkinson's disease and Lewy body dementia. Additionally, PMN442 focuses on toxic alpha-synuclein oligomers and seeding fibrils linked to MSA. These innovative therapies aim to halt disease progression by specifically targeting the underlying molecular mechanisms driving neurodegeneration.
Founded in 2004 as Amorfix Life Sciences Ltd. and rebranded as ProMIS Neurosciences, Inc. in 2015, the company is headquartered in Toronto, Canada. ProMIS Neurosciences continues to advance its cutting-edge research and development efforts, leveraging its deep understanding of disease pathology to advance novel treatments that offer hope to patients affected by neurodegenerative disorders worldwide.